The addition of daratumumab to the triplet bortezomib, thalidomide, and dexamethasone (VTd) induction and consolidation in transplant-eligible patients with newly diagnosed multiple myeloma improved both the depth of response and progression-free survival (PFS) compared with VTd alone .
Prof. Phillippe Moreau (University Hospital of Nantes, France) discussed the findings from the randomised, open-label, multicentre, phase 3 CASSIOPEIA trial and the potential role for daratumumab in patients with newly diagnosed multiple myeloma in combination with standard-of-care VTd for patients who are candidates for autologous stem cell transplantation (ASCT).
Patients (n=1,085) were enrolled and randomly assigned to VTd induction and consolidation either with (n=543) or without (n=542) the addition of daratumumab (Dara-VTd) followed by high-dose melphalan and ASCT. The stringent complete response ...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Introduction to the Conference Report of the EHA Next Article
New sickle cell drug voxelotor boosts levels of haemoglobin »
Table of Contents: EHA 2019
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.